Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company that regularly issues news on its business segments, financing activities, partnerships and product pipeline. As an ophthalmic goods manufacturer with operations in vision care, surgical products and ophthalmic pharmaceuticals, the company’s announcements cover a broad range of topics relevant to investors and those following the eye health sector.
News updates include financial results, such as quarterly revenue performance across the Vision Care, Surgical and Pharmaceuticals segments, as well as details on operating income, adjusted metrics and guidance ranges. The company also uses press releases to outline strategic plans and multi-year financial targets, describe its product pipeline in areas like dry eye, glaucoma, ocular surface pain and age-related macular degeneration, and highlight clinical-stage programs and anticipated launches across consumer, pharmaceutical, surgical and contact lens businesses.
Bausch + Lomb’s news flow also features information on capital structure and liquidity, including amendments to its credit agreement, new term loan tranches, revolving credit facilities and senior secured notes offerings, along with the intended use of proceeds for refinancing existing debt. Governance and leadership developments, such as board appointments, committee assignments and changes related to director nomination agreements, are disclosed through current reports and accompanying press releases.
In addition, the company issues news about partnerships and initiatives in eye health, including collaborations with organizations focused on glaucoma research and awareness, and sustainability programs like the ONE by ONE Recycling Program and the Every Contact Counts program. For readers tracking BLCO, this news page aggregates these updates so they can review company communications on financial performance, strategic direction, product development, governance and eye health initiatives in one place.
Bausch + Lomb (NYSE/TSX: BLCO) has announced a voluntary recall of its enVista platform intraocular lenses (IOLs), including enVista Aspire™, enVista Envy™, and certain enVista® monofocal models. The recall was initiated following reports of toxic anterior segment syndrome (TASS) complications in some patients.
TASS, an inflammatory reaction that typically manifests 12-48 hours post-cataract surgery, has been reported in a small percentage of implanted lenses. Chairman and CEO Brent Saunders emphasized that all reported TASS cases responded well to treatment, with no lens removals required. The company is prioritizing patient safety and is currently communicating with eye care professionals regarding impacted lots and return protocols while working to identify the root cause.
Bausch + Lomb (NYSE/TSX: BLCO) announced it will release its first-quarter 2025 financial results on Wednesday, April 30, 2025. The global eye health company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be available on the company's Investor Relations website section before the call begins.
Bausch + Lomb (NYSE/TSX: BLCO) has launched Arise™, an innovative orthokeratology lens system in the United States. The system features intelligent cloud-based technology that streamlines the lens design process for treating myopia (nearsightedness).
The Arise platform includes the first FDA-approved orthokeratology lens design with toric peripheral curves for overnight myopia treatment. The system efficiently syncs with topographers to create precise lens designs in seconds, eliminating the need for fitting sets. Its advanced algorithms interpret corneal topography images instantly and include an overnight outcome map library for evaluating lens centration and patient progress.
This launch addresses a significant market need, as myopia affects approximately 28% of the global population (2 billion people), with projections showing an increase to 50% (5 billion people) by 2050. The platform is currently available in the United States, United Kingdom, and Europe.
Bausch + Lomb (NYSE/TSX: BLCO) reported Q4 2024 revenue of $1.280 billion, up 9% year-over-year, with an 11% increase on a constant currency basis. The company posted a Q4 GAAP net loss of $3 million.
Full-year 2024 revenue reached $4.791 billion, representing a 16% increase, with growth across all segments. Vision Care revenue grew to $2.739 billion (+8%), Surgical revenue reached $843 million (+10%), and Pharmaceuticals revenue increased to $1.209 billion (+45%).
For 2025, the company projects revenue between $4.950-$5.050 billion, representing 5.5-7.5% constant currency growth, and Adjusted EBITDA of $900-$950 million. The guidance factors in foreign exchange headwinds of -$100M for revenue and -$20M for Adjusted EBITDA.
Bausch + Lomb (NYSE/TSX: BLCO) has announced that its exploration of potential privatization with a third-party buyer has concluded without resulting in a transaction. The company had previously disclosed this possibility in December 2024 following a regulatory request. Full separation from Bausch Health Companies Inc. remains the company's objective.
The eye health company continues to operate independently and execute its business strategies. Notably, BLCO raised its 2024 revenue guidance on October 30 and will report its fourth-quarter and full-year 2024 earnings on February 19, along with providing guidance for fiscal year 2025.
Bausch + Lomb (NYSE/TSX: BLCO) has scheduled the release of its fourth-quarter and full-year 2024 financial results for Wednesday, February 19, 2025. The global eye health company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update.
The company will make all materials available on their Investor Relations website before the call. Participants can join via webcast or through dial-in numbers for North America (+1-888-506-0062) and International (+1-973-528-0011) using access code 785090. A replay will be available until March 5, 2025.
Bausch + Lomb (NYSE/TSX: BLCO), a global leader in eye health, announced the acquisition of Whitecap Biosciences, , enhancing its clinical-stage pipeline. Whitecap is developing two innovative therapies for glaucoma and geographic atrophy (GA). Whitecap Biosciences, founded in 2015, focuses on novel treatments for serious eye diseases, successfully completing Phase 2 trials for WB007 in glaucoma, a potent alpha-2 adrenergic agonist. Further trials are planned for both glaucoma and GA. Glaucoma, a progressive neurodegenerative disease, affects about four million people in the U.S. and is a leading cause of preventable blindness. GA, also known as advanced dry age-related macular degeneration, affects approximately one million people in the U.S. By joining Bausch + Lomb, Whitecap aims to develop its assets into effective treatments to improve visual outcomes.
Bausch + Lomb (NYSE/TSX: BLCO) has announced the commercial launch of enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union following CE Mark approval. The enVista Aspire combines Intermediate Optimized optics for broader depth of focus with the established enVista platform benefits.
The product features include glistening-free optic material and StableFlex Technology for controlled unfolding. The toric version offers treatment for astigmatism during cataract surgery with a +0.90 cylinder design and AccuSet haptic design for rotational stability.
The IOLs are indicated for primary implantation in adult patients for visual correction of aphakia following cataract lens removal, with the toric version specifically addressing corneal astigmatism. The device uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter.
Outcome Capital announces the successful acquisition of Elios Vision by Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, a developer of minimally invasive glaucoma surgery (MIGS) using excimer laser technology, has created the ELIOS™ procedure, an implant-free treatment designed to reduce intraocular pressure in glaucoma patients while minimizing risks associated with traditional surgeries.
The technology is currently CE-marked and available in the European Union, with FDA approval being sought this year. The procedure can be performed standalone or alongside cataract surgery, offering broader adoption potential due to its relative simplicity compared to implant-based MIGS. The acquisition strengthens Bausch + Lomb's position in the $2.5 billion glaucoma treatment market, addressing a condition that affects over 76 million people globally.
Bausch + Lomb (NYSE/TSX: BLCO) and Glaucoma Research Foundation (GRF) are launching their second annual 'Faces of Glaucoma' campaign during Glaucoma Awareness Month in January. The initiative aims to raise awareness about glaucoma, the second leading cause of blindness worldwide, by sharing diverse patient stories and educational resources.
The campaign highlights that approximately half of people with glaucoma are unaware they have the condition. As part of the initiative, Bausch + Lomb will match donations up to $20,000 for the fourth consecutive year to support GRF's research toward finding a cure.
The campaign emphasizes that while glaucoma is often associated with older individuals, it can affect anyone regardless of race, age, or gender. Early intervention, including prescription eye drops, can help slow the disease's progression, though there is currently no cure. Detection requires yearly comprehensive dilated eye exams by eye care professionals.